1. Home
  2. HDL vs GYRE Comparison

HDL vs GYRE Comparison

Compare HDL & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HDL

SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares

N/A

Current Price

$17.00

Market Cap

1.1B

ML Signal

N/A

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

HOLD

Current Price

$7.07

Market Cap

755.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HDL
GYRE
Founded
2016
2002
Country
Singapore
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
755.7M
IPO Year
2024
N/A

Fundamental Metrics

Financial Performance
Metric
HDL
GYRE
Price
$17.00
$7.07
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$17.00
AVG Volume (30 Days)
2.0K
86.4K
Earning Date
11-26-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.04
0.04
Revenue
$820,865,000.00
$107,265,000.00
Revenue This Year
$11.19
$11.59
Revenue Next Year
$13.37
$26.31
P/E Ratio
$53.97
$182.16
Revenue Growth
8.02
2.13
52 Week Low
$16.30
$6.11
52 Week High
$30.00
$14.42

Technical Indicators

Market Signals
Indicator
HDL
GYRE
Relative Strength Index (RSI) 43.24 38.17
Support Level $16.99 $7.36
Resistance Level $17.49 $7.70
Average True Range (ATR) 0.22 0.37
MACD -0.04 -0.08
Stochastic Oscillator 18.40 14.08

Price Performance

Historical Comparison
HDL
GYRE

About HDL SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares

Super Hi International Holding Ltd is an investment holding company and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. Its mission is to become a world-wide integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: